Analyzing...
Loading company...
Wockhardt Ltd. engages in the pharmaceutical business. The company is headquartered in Mumbai, Maharashtra and currently employs 2,962 full-time employees. The firm's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. The company manufactures a range of dosage forms, including sterile injectables and lyophilized products. The firm offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Company’s products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. The firm has approximately three research centers globally and a chain of six super-specialty hospitals across Maharashtra and Gujarat.
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹3,373 Cr revenue.
COGS 33.6%, employees 21.5%.
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 4.3%▼ | 10.3% |
| ROCE | 6.5%▼ | 13.7% |
| Net Margin | 6.1%▼ | 7.6% |
| EBITDA Margin | 19.5%▲ | 15.4% |
| Debt To Equity | 0.43x▲ | 0.15x |
| Rev Growth 3yr | 7.9%▼ | 10.0% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,373 Cr +12.0% | ₹3,012 Cr +7.6% | ₹2,798 Cr +5.5% | ₹2,651 Cr -17.9% | ₹3,230 Cr +19.3% | ₹2,708 Cr -4.8% | ₹2,844 Cr -31.6% | ₹4,158 Cr |
| Other Income | ₹111 Cr +79.0% | ₹62 Cr -25.3% | ₹83 Cr -32.0% | ₹122 Cr +510.0% | ₹20 Cr -84.9% | ₹132 Cr +240.8% | ₹39 Cr +84.6% | ₹21 Cr |
| Total Income | ₹3,484 Cr +13.3% | ₹3,074 Cr +6.7% | ₹2,881 Cr +3.9% | ₹2,773 Cr -14.7% | ₹3,250 Cr +14.4% | ₹2,841 Cr -1.5% | ₹2,883 Cr -31.0% | ₹4,179 Cr |
| COGS | ₹1,132 Cr 0.0% | ₹1,132 Cr -2.8% | ₹1,165 Cr +4.9% | ₹1,111 Cr -12.3% | ₹1,267 Cr +11.6% | ₹1,135 Cr -5.6% | ₹1,203 Cr -33.7% | ₹1,815 Cr |
| ₹3,161 Cr +2.3% | ₹3,090 Cr -6.0% | ₹3,287 Cr +5.9% | ₹3,103 Cr -10.8% | ₹3,478 Cr +6.5% | ₹3,266 Cr +1.3% | ₹3,225 Cr -28.0% | ₹4,480 Cr | |
| Profit Before Tax | ₹238 Cr ↑ Recovery | (₹16 Cr) +96.2% | (₹420 Cr) +32.7% | (₹624 Cr) -51.8% | (₹411 Cr) +27.7% | (₹568 Cr) -66.2% | (₹342 Cr) -13.9% | (₹300 Cr) |
| Exceptional Items | (₹85 Cr) | ₹0.00 Cr +100.0% | (₹14 Cr) +95.2% | (₹294 Cr) -60.7% | (₹183 Cr) -28.4% | (₹142 Cr) | ₹0.00 Cr | ₹0.00 Cr |
| ₹39 Cr -4.9% | ₹41 Cr -21.2% | ₹52 Cr ↑ Recovery | (₹3 Cr) +97.7% | (₹132 Cr) +51.4% | (₹272 Cr) -33.1% | (₹204 Cr) -144.0% | (₹84 Cr) | |
| Net Profit | ₹199 Cr ↑ Recovery | (₹57 Cr) +87.9% | (₹472 Cr) +24.0% | (₹621 Cr) -122.6% | (₹279 Cr) ↓ Decline | ₹689 Cr ↑ Recovery | (₹43 Cr) +80.0% | (₹217 Cr) |
| Profit (Owners) | ₹213 Cr ↑ Recovery | (₹47 Cr) +89.8% | (₹463 Cr) +17.2% | (₹559 Cr) -129.1% | (₹244 Cr) ↓ Decline | ₹686 Cr ↑ Recovery | (₹69 Cr) +64.4% | (₹195 Cr) |
| Minority Interest | (₹14 Cr) -40.0% | (₹10 Cr) -11.1% | (₹9 Cr) +85.5% | (₹62 Cr) -77.1% | (₹35 Cr) ↓ Decline | ₹3 Cr -90.2% | ₹26 Cr ↑ Recovery | (₹22 Cr) |
| Other Comprehensive Income | ₹419 Cr +490.1% | ₹71 Cr | ₹6 Cr -92.3% | ₹78 Cr ↑ Recovery | (₹27 Cr) -578.4% | (₹4 Cr) ↓ Decline | ₹101 Cr | ₹9 Cr |
| EPS | ₹13.11 | (₹2.89) | (₹30.18) | (₹38.80) | (₹16.94) | ₹47.64 | (₹4.81) | (₹13.52) |
| Diluted Shares | ₹16 Cr | ₹16 Cr | ₹15 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr | ₹14 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.
Pursuant to Regulation 30 read with Schedule III (Part A Para A) and other applicable regulations of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the ...
The 27th Annual General Meeting ( 27th AGM ) of the Members of Wockhardt Limited will be held on Monday, 10th August, 2026 at 3:30 p.m. (IST), through Video Conferencing ( VC )/ Other Audio Visual Mea...
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, please findenclosed the Certificate received from MUFG Intime India Private Limited, Registrar and Share Transfe...
Wockhardt Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations,...
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations andDisclosure Requirements) Regulations, 2015, as amended and in continuation to our letter bearing referen...
Wockhardt Limited has informed the Exchange about Investor Presentation
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release titled, Indian drug regulator grants marketing authorization to Wockhardt's breakthrough antibiotic, ZAYNICH® (Zide...
Wockhardt Limited has informed the Exchange about Credit Rating
Pursuant to Regulation 30 of the Listing Regulations, please find enclosed Press Release on theAudited Financial Results (Standalone and Consolidated) for the quarter and the financial yearended 31st ...
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing R...
Pursuant to Regulation 30 and 33 of Listing Regulations read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing R...
Pursuant to Regulation 30 of Listing Regulations, please find enclosed Press Release -"Wockhardt's Zaynich® (Zidebactam/Cefepime) Receives Favourable Recommendation from CDSCO's Subject Expert Committ...
Wockhardt Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Pursuant to Regulation 30 read with Schedule III part A para A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the newspaperadvertisement...
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024, we wish ...